Effect of Romosozumab on Bone Metabolism, Lipid Profile, and Laboratory Parameters in Real-World Clinical Practice. (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2555; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "This study suggests a good retention rate for Romosozumab after 12 months of treatment, along with a significant improvement in bone mineral density, particularly in the lumbar spine. No adverse impact on lipid profiles was observed during follow-up. Furthermore, densitometric efficacy and changes in bone metabolism parameters were comparable regardless of the treatment line, supporting the use of Romosozumab in both first-line and subsequent lines of therapy."
Clinical • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia • Musculoskeletal Diseases • Orthopedics • Osteoporosis
|
|
Mitndbaim Aelohim Parra Moreno1; Clementina López Medina2; Andrea Cid Cháves3; Alejandro Escudero Contreras4; Asuncion Salmoral Chamizo1
|